HTDS commences clinical trials for MEVAC-A vaccine in Vietnam

Hard to Treat Diseases, Inc. (HTDS; and Shenzhen Mellow Hope ( announce, that the company commenced clinical trials for the company's Hepatitis A (brand name MEVAC-A) vaccine.

Following 2 years of cooperation with the Vietnamese Ministry of Health, HTDS reached the stage of clinical trials for its MEVAC-A. To complete the trials, the company obtained the Import License for the samples, and expects to ship those to Vietnam in June 2010.

The company expects to finalize the clinical trials within 6 months. Following the trials, Vietnamese Ministry of Health will release Registration Certificate for the vaccine immediately and the company will start to market its product on this growing market (Domestic growth shown 7% increase from 2000 to 2005).

A source close to the company stated, "The past two years we worked closely with the Vietnamese authorities and now is the time for us to finish and reap the results. We expect to gain a solid spot on the Vietnamese vaccine market. With the Vietnam's population of over 85 million, we expect to ship large quantities of our product to the country and bring solid profits to HTDS and its shareholders."


Hard to Treat Diseases

Posted in: Drug Trial News | Disease/Infection News

Tags: , , , ,



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Researchers overcome major stumbling blocks in developing HIV vaccine